Published on in Vol 6, No 8 (2017): August

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Combination Analgesic Development for Enhanced Clinical Efficacy (CADENCE Trial): Study Protocol for a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of an Alpha-Lipoic Acid – Pregabalin Combination for the Treatment of Fibromyalgia Pain

Ian Gilron   1 , MSc, MD ;   Dongsheng Tu   2 , PhD ;   Ronald Holden   2 , PhD ;   Tanveer Towheed   2 , MD ;   Elizabeth Vandenkerkhof   2 , DrPH ;   Roumen Milev   2 , MD, PhD

1 Queen's University, Department of Anesthesiology and Perioperative Medicine, Queen's University, Kingston, ON, Canada

2 Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, ON, Canada

Corresponding Author:

  • Ian Gilron, MSc, MD
  • Queen's University
  • Department of Anesthesiology and Perioperative Medicine
  • Queen's University
  • Kingston General Hospital
  • 76 Stuart Street, Victory 2 Pavillion
  • Kingston, ON
  • Canada
  • Phone: 1 613 549 6666 ext 3963
  • Fax: 1 613 548 1375
  • Email: gilroni@queensu.ca